Umuthi Wokuqala Ohlanganisiwe Womthamo Ogxilile Wethulwe Yesifo Sikashukela Sohlobo 2

I-Glenmark Pharmaceuticals Limited yethule inhlanganisela enoveli yomthamo ongaguquki (FDC) we-DPP4 inhibitor esetshenziswa kabanzi (i-Dipeptidyl Peptidase 4 inhibitor), i-Teneligliptin, ne-Pioglitazone. Lona ukuphela komkhiqizo wenhlanganisela ye-DPP4 kanye ne-Glitazone e-India kubantu abadala abanesifo sikashukela sohlobo 2 esingalawuleki. I-Glenmark yethule le-FDC ngaphansi kwegama lomkhiqizo i-Zita Plus Pio, equkethe i-Teneligliptin (20 mg) + i-Pioglitazone (15 mg), okumele iphuzwe kanye ngosuku.

Ephawula ngentuthuko, u-Alok Malik, iPhini Likamongameli Weqembu kanye neNhloko, i-India Formulations – Glenmark Pharmaceuticals, uthe, “Isifo sikashukela siyindawo esemqoka yeGlenmark; iphayona ekunikezeni ukufinyelela kwezindlela zokwelapha zakamuva ezigulini ezinesifo sikashukela eNdiya. Siyajabula ukwethula le noveli iZita Plus Pio, okungeyokuqala ngqa eNdiya; inikeza indlela yokwelapha esezingeni lomhlaba futhi ethengekayo ezigulini ezinesifo sikashukela esibadala.”

IGlenmark yinkampani yokuqala e-India ukumaketha i-FDC esunguliwe ye-Teneligliptin + Pioglitazone, egunyazwe i-DCGI (Drug Controller General of India). Le nhlanganisela yomthamo ongaguquki izoba wusizo ezigulini ezidinga ukwelashwa nge-Teneliglitptin ne-Pioglitazone (njengemithi ehlukene) ukuze kuthuthukiswe ukulawulwa kwe-glycemic kwehlisa Ukumelana Ne-insulin. 

Abanesifo sikashukela sohlobo 2 ngokuvamile babhekana nezinkinga zokungasebenzi kahle kwamaseli e-β kanye nokumelana ne-insulin. I-FDC ye-Glenmark ye-Teneligliptin + Pioglitazone inamandla okubhekana nalawa ma-pathophysiologies amabili abaluleke kakhulu okwenza i-FDC iphumelele kakhulu ekulawuleni isifo sikashukela soHlobo lwesi-2 esingalawuleki. Inhlanganisela ye-Teneligliptin + Pioglitazone izohlinzeka ngendlela evumelanayo lapho i-Teneligliptin izothuthukisa ngokugcwele ukuzwela kwe-β cell, futhi i-Pioglitazone izokwehlisa ngempumelelo ukumelana ne-insulin.

Igalelo likaGlenmark ekwelapheni isifo sikashukela

Ngo-2015, iGlenmark yaguqula imakethe yesifo sikashukela ngokwethula i-DPP4 inhibitor - iTeneligliptin eNdiya, yalandelwa yi-FDC yeTeneligliptin + Metformin. I-Glenmark inefa eliqinile leminyaka engaphezu kwamashumi amane yenqubekela phambili nokuqamba izinto ezintsha. Ngokuqhubeka nokuya okokuqala emlandweni wase-India, yethule i-FDC ye-Teneligliptin + Remogliflozin ngo-2021.

I-India yaziwa njengenhloko-dolobha yesifo sikashukela emhlabeni. Ngokusho kwe-International Diabetes Federation (IDF), ukusabalala kwesifo sikashukela e-India kuzungeze abantu abadala abayizigidi ezingama-74, okulindeleke ukuthi kwenyuke kufinyelele ezigidini eziyi-125 (cishe ukwanda okungama-70%) ngo-2045[i]. Kulezi, u-77% weziguli unesifo sikashukela esingalawuleki.